Guggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by equities researchers at Guggenheim from $12.00 to $8.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 131.21% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Oppenheimer reissued an “outperform” rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective for the company in a research note on Monday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL traded down $0.49 during mid-day trading on Friday, hitting $3.46. The company had a trading volume of 1,133,022 shares, compared to its average volume of 1,327,512. Zentalis Pharmaceuticals has a one year low of $2.66 and a one year high of $18.07. The firm has a fifty day moving average price of $3.41 and a 200 day moving average price of $5.52. The company has a market capitalization of $246.58 million, a PE ratio of -1.39 and a beta of 1.74.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Erste Asset Management GmbH purchased a new position in Zentalis Pharmaceuticals in the third quarter valued at approximately $37,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals in the 3rd quarter worth about $37,000. Anfield Capital Management LLC bought a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at about $40,000. Aigen Investment Management LP bought a new position in Zentalis Pharmaceuticals during the third quarter worth about $41,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth about $48,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.